BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 31, 2017--
Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development, manufacturing and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that it will report third quarter 2017 financial results on
Tuesday, November 7, 2017. Following distribution of the earnings
release via wire services, the Ocular Therapeutix management team will
host a live conference call and webcast at 5:00 p.m. Eastern Time to
review the Company’s financial results and provide a general business
The live webcast can be accessed by visiting the Investors section of
the Company’s website at investors.ocutx.com.
Please connect at least 15 minutes prior to the live webcast to ensure
adequate time for any software download that may be needed to access the
webcast. Alternatively, please call (844) 464-3934 (U.S.) or (765)
507-2620 (International) to listen to the live conference call. The
conference ID number for the live call will be 7468418. An archive of
the webcast will be available until November 21, 2017 on the Company’s
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development, manufacturing and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix’s lead product candidate,
DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has
completed Phase 3 clinical development for the treatment of ocular pain
and inflammation following ophthalmic surgery. OTX-TP (travoprost
insert) is in Phase 3 clinical development for the reduction of
intraocular pressure in patients with glaucoma and ocular hypertension.
The Company’s earlier stage assets include OTX-TIC, a sustained release
travoprost intracameral injection for the treatment of moderate to
severe glaucoma and ocular hypertension, as well as sustained release
intravitreal injections for the treatment of retinal diseases. These
injections include the development of OTX-TKI, a tyrosine kinase
inhibitor (TKI), and, in collaboration with Regeneron, an extended
release protein-based anti-vascular endothelial growth factor (VEGF)
trap. Ocular Therapeutix's first product, ReSure® Sealant, is
FDA-approved to seal corneal incisions following cataract surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171031005517/en/
Source: Ocular Therapeutix, Inc.
Steve Klass, 212-213-0006
Chief Financial Officer
Vice President of Marketing &